Navigation Links
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Date:3/20/2017

MENLO PARK, Calif., March 20, 2017 /PRNewswire/ -- Forty Seven Inc., a clinical-stage immuno-oncology company announced today that Mark A. McCamish, M.D., Ph.D., will join the company on May 1 as President and CEO. 

Dr. McCamish, who was most recently Global Head of Biopharmaceutical Development at Sandoz Inc., succeeds the founding CEO, Jonathan MacQuitty, Ph.D. Dr. MacQuitty, who is now a Venture Partner at Lightspeed Venture Partners, will remain on the company's Board of Directors.

"Forty Seven has made unprecedented progress to date based on the remarkable science initiated by the world-class efforts of Dr. Irv Weissman and Dr. Ravi Majeti and their combined team at Stanford University. In addition, Jonathan MacQuitty has assembled an amazing team at the company," said Dr. McCamish. "Forty Seven's technology provides a unique opportunity to harness the power of the innate immune system to help patients defeat their own cancer."

Jonathan MacQuitty said, "Mark has demonstrated exceptional leadership capabilities, as well as a unique combination of late-phase biological drug development, scientific understanding, and a passion for patient benefit that will lead Forty Seven into the future."

Mark has been an executive at several companies including Abbott Labs, Amgen, and PDL Biopharma. Most recently he helped pioneer global biosimilar development at Novartis' Sandoz division. Mark led the Sandoz team at the first ever US FDA Oncology Drug Advisory Committee evaluation of a biosimilar (filgrastim) resulting in a unanimous endorsement and followed that by obtaining a unanimous endorsement of Sandoz' second US biosimilar (etanercept) by the US FDA Arthritis Advisory Committee.  Under his guidance, Sandoz Biopharmaceuticals Development has emerged as a leader in the field having filed several BLA's through September 2016, when Mark retired from Sandoz.

About Forty Seven Inc.

Forty Seven Inc. is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by the immune system. This antibody is currently being evaluated in four Phase 1 clinical studies in the US and the UK in patients with solid tumors or cutaneous T-cell lymphoma (CTCL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC).

Forty Seven is located at 1490 O'Brien Drive, Suite A, Menlo Park, CA 94025, U.S.A.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forty-seven-inc-announces-mark-mccamish-md-phd-to-join-as-ceo-on-may-1st-300426601.html


'/>"/>
SOURCE Forty Seven Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Forty of Nations Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists
2. Kalorama Information Names Top Seven Companies in Point-of-Care Diagnostics
3. Breckenridge Pharmaceutical signs Marketing Agreement with Gland Pharma Limited for Seven Injectable Products
4. Transformative Potential of Elektas High-field MR-guided Linear Accelerator Highlighted in Seven Abstracts at ESTRO 35
5. Sysmex America, Inc. Named to Center for Companies That Care Honor Roll for Seventh Time
6. Seventeen Organizations Now Utilizing Heritage Provider Networks "QHMO" Suite Of Care Coordination Tools
7. Northern Light Wraps Up Successful 2015 with the Addition of Seven Fortune 1000 Clients
8. Wins Finance Holdings Inc. Enters the Tele-medical Equipment Leasing Sector in China, Signing Seven Agreements Valued at RMB 49.5 Million (US$7.7 Million)
9. Avalon Ventures Expands Collaboration with GSK and Launches Seventh New Company at COI Pharmaceuticals
10. Biophor Diagnostics, Inc. Announces Seventh FDA 510(k) Clearance, Completing Panel of Rapid, Homogeneous Screening Tests for Drugs of Abuse in Oral Fluid
11. Seven US Medical Centers to Acquire Elektas New Leksell Gamma Knife Icon Brain Radiosurgery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):